<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363871">
  <stage>Registered</stage>
  <submitdate>24/03/2013</submitdate>
  <approvaldate>24/04/2013</approvaldate>
  <actrnumber>ACTRN12613000464763</actrnumber>
  <trial_identification>
    <studytitle>ASR Hip Resurfacing, Chrome and Cobalt Levels and Effect on Vision</studytitle>
    <scientifictitle>Do patients with an ASR hip replacement have elevated blood chrome and cobalt levels and does this cause visual disturbances when compared to the normal population </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Failed Hip Replacement</healthcondition>
    <healthcondition>Cobalt and Chrome Toxicity</healthcondition>
    <healthcondition>Visual Disturbances</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Visual acuity in patients with the ASR Hip Replacements
Single assessment made; duration of observation 4hour session
</interventions>
    <comparator>The control group will be a healthy cohort of patients who have not had the ASR prosthesis implanted</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual Disturbance recorded via visual electrophysiology</outcome>
      <timepoint>Single time point in each participant. Any time after prosthesis insertion, assuming the primary joint remains in situ (i.e. not revised)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum assay of Chrome and Cobalt levels</outcome>
      <timepoint>Single time point in each participant. Any time after prosthesis insertion, assuming the primary joint remains in situ (i.e. not revised)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ASR Hip Replacement</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Known visual problems</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Patients will undertake visual electrophysiology to identify if a significant difference (using a P Value &lt;0.05) exists with patients who have an ASR Hip replacement and visual disturbances compared to the population without an ASR Hip replacement</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2012</anticipatedstartdate>
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate>31/12/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sir Charles Gairdner Hospital</primarysponsorname>
    <primarysponsoraddress>Hospital Ave, Nedlands, WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>De Puy</fundingname>
      <fundingaddress>Number One
White Rose Office Park
Millshaw Park Lane
Leeds
LS11 0EA
UK</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NIL</sponsorname>
      <sponsoraddress>NIL</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to measure blood levels of Chrome and Cobalt in patients with an ASR Hip replacement in situ and to see if these patients have visual disturbances</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Group Human Research Ethics Committee</ethicname>
      <ethicaddress>Hospital Ave Nedlands Western Australia 6009</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Riaz Khan</name>
      <address>Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, Western Australia 6009</address>
      <phone>+618 9346 3333</phone>
      <fax />
      <email>rjkkhan@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Timothy Unsworth-smith</name>
      <address>Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, Western Australia 6009</address>
      <phone>+618 9346 3333</phone>
      <fax />
      <email>timusmith@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Timothy Unsworth-smith</name>
      <address>Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, Western Australia 6009</address>
      <phone>+618 9346 3333</phone>
      <fax />
      <email>timusmith@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Timothy Unsworth-smith</name>
      <address>Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, Western Australia 6009</address>
      <phone>+618 9346 3333</phone>
      <fax />
      <email>timusmith@hotmail.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>